カテゴリー： QYResearch, 世界

ホルモン抵抗性乳癌の世界市場：規模・現状・予測

◆英語タイトル：Global Hormone Refractory Breast Cancer Market Size, Status and Forecast 2019-2025
◆商品コード：DATA909X18546
◆発行会社（リサーチ会社）：QYResearch
◆発行日：2019年11月25日（※2024年版があります。お問い合わせください）
◆ページ数：96
◆レポート形式：英語 / PDF
◆納品方法：Eメール（受注後3営業日）
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）

Single User（1名様閲覧用）	USD3,900 ⇒換算￥577,200	見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）	USD5,850 ⇒換算￥865,800	見積依頼/購入/質問フォーム
Enterprise License（同一法人内共有可）	USD7,800 ⇒換算￥1,154,400	見積依頼/購入/質問フォーム

★QYResearchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

※当調査レポートでは、ホルモン抵抗性乳癌の世界市場について調査・分析し、ホルモン抵抗性乳癌の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（腫瘍マーカー療法、遺伝子発現療法、遺伝子突然変異療法）、用途別（科学研究生産、生物科学技術、医療技術、医療機器）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。

・レポートの概要
・世界のホルモン抵抗性乳癌市場動向
・主要企業別マーケットシェア
・ホルモン抵抗性乳癌の種類別市場規模2014-2019
（腫瘍マーカー療法、遺伝子発現療法、遺伝子突然変異療法）
・ホルモン抵抗性乳癌の用途別市場規模2014-2019
（科学研究生産、生物科学技術、医療技術、医療機器）
・ホルモン抵抗性乳癌の北米市場：主要企業・種類別/用途別市場規模
・ホルモン抵抗性乳癌のヨーロッパ市場：主要企業・種類別/用途別市場規模
・ホルモン抵抗性乳癌の中国市場：主要企業・種類別/用途別市場規模
・ホルモン抵抗性乳癌の日本国内市場：主要企業・種類別/用途別市場規模
・ホルモン抵抗性乳癌の東南アジア市場：主要企業・種類別/用途別市場規模
・ホルモン抵抗性乳癌のインド市場：主要企業・種類別/用途別市場規模
・ホルモン抵抗性乳癌の中南米市場：主要企業・種類別/用途別市場規模
・主要企業のプロフィール
（AstraZeneca、AmpliMed Corporation、Roche、Bluefish Pharmaceuticals AB、NeoCorp、Sanofi Genzyme、Neopharm、Boehringer Ingelheim GmbH）
・ホルモン抵抗性乳癌の市場規模予測2019-2025
（種類別、用途別、地域別市場予測）
・アナリストの観点・結論
...

【レポートの概要】

An increasing number of hormone therapies have made refractory breast cancer resistant to treatment, increased incidence of breast cancer, aging population, increased demand for advanced therapies, increased incidence of hormone-refractory breast cancer and the existence of a large number of anti-cancer pipeline drugs, all of which drive the growth of hormone-refractory breast cancer market.In 2018, the global Hormone Refractory Breast Cancer market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

This report focuses on the global Hormone Refractory Breast Cancer status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Hormone Refractory Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
AstraZeneca
AmpliMed Corporation
Roche
Bluefish Pharmaceuticals AB
NeoCorp
Sanofi Genzyme
Neopharm
Boehringer Ingelheim GmbH

Market segment by Type, the product can be split into
Tumor Markers Therapy
Gene Expression Therapy
Gene Mutation Therapy

Market segment by Application, split into
Scientific Research and Production
Biological Science and Technology
Medical Technology
Medical Apparatus and Instruments

Market segment by Regions/Countries, this report covers
North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global Hormone Refractory Breast Cancer status, future forecast, growth opportunity, key market and key players.
To present the Hormone Refractory Breast Cancer development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Hormone Refractory Breast Cancer are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type (2014-2025)
1.4.2 Tumor Markers Therapy
1.4.3 Gene Expression Therapy
1.4.4 Gene Mutation Therapy
1.5 Market by Application
1.5.1 Global Hormone Refractory Breast Cancer Market Share by Application (2019-2025)
1.5.2 Scientific Research and Production
1.5.3 Biological Science and Technology
1.5.4 Medical Technology
1.5.5 Medical Apparatus and Instruments
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 Hormone Refractory Breast Cancer Market Size
2.2 Hormone Refractory Breast Cancer Growth Trends by Regions
2.2.1 Hormone Refractory Breast Cancer Market Size by Regions (2019-2025)
2.2.2 Hormone Refractory Breast Cancer Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis

3 Market Share by Key Players
3.1 Hormone Refractory Breast Cancer Market Size by by Players
3.1.1 Global Hormone Refractory Breast Cancer Revenue by by Players (2014-2019)
3.1.2 Global Hormone Refractory Breast Cancer Revenue Market Share by by Players (2014-2019)
3.1.3 Global Hormone Refractory Breast Cancer Market Concentration Ratio (CR5 and HHI)
3.2 Hormone Refractory Breast Cancer Key Players Head office and Area Served
3.3 Key Players Hormone Refractory Breast Cancer Product/Solution/Service
3.4 Date of Enter into Hormone Refractory Breast Cancer Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global Hormone Refractory Breast Cancer Market Size by Type (2014-2019)
4.2 Global Hormone Refractory Breast Cancer Market Size by Application (2014-2019)

5 North America
5.1 North America Hormone Refractory Breast Cancer Market Size (2014-2019)
5.2 Hormone Refractory Breast Cancer Key Players in North America
5.3 North America Hormone Refractory Breast Cancer Market Size by Type
5.4 North America Hormone Refractory Breast Cancer Market Size by Application

6 Europe
6.1 Europe Hormone Refractory Breast Cancer Market Size (2014-2019)
6.2 Hormone Refractory Breast Cancer Key Players in Europe
6.3 Europe Hormone Refractory Breast Cancer Market Size by Type
6.4 Europe Hormone Refractory Breast Cancer Market Size by Application

7 China
7.1 China Hormone Refractory Breast Cancer Market Size (2014-2019)
7.2 Hormone Refractory Breast Cancer Key Players in China
7.3 China Hormone Refractory Breast Cancer Market Size by Type
7.4 China Hormone Refractory Breast Cancer Market Size by Application

8 Japan
8.1 Japan Hormone Refractory Breast Cancer Market Size (2014-2019)
8.2 Hormone Refractory Breast Cancer Key Players in Japan
8.3 Japan Hormone Refractory Breast Cancer Market Size by Type
8.4 Japan Hormone Refractory Breast Cancer Market Size by Application

9 Southeast Asia
9.1 Southeast Asia Hormone Refractory Breast Cancer Market Size (2014-2019)
9.2 Hormone Refractory Breast Cancer Key Players in Southeast Asia
9.3 Southeast Asia Hormone Refractory Breast Cancer Market Size by Type
9.4 Southeast Asia Hormone Refractory Breast Cancer Market Size by Application

10 India
10.1 India Hormone Refractory Breast Cancer Market Size (2014-2019)
10.2 Hormone Refractory Breast Cancer Key Players in India
10.3 India Hormone Refractory Breast Cancer Market Size by Type
10.4 India Hormone Refractory Breast Cancer Market Size by Application

11 Central & South America
11.1 Central & South America Hormone Refractory Breast Cancer Market Size (2014-2019)
11.2 Hormone Refractory Breast Cancer Key Players in Central & South America
11.3 Central & South America Hormone Refractory Breast Cancer Market Size by Type
11.4 Central & South America Hormone Refractory Breast Cancer Market Size by Application

12 International Players Profiles
12.1 AstraZeneca
12.1.1 AstraZeneca Company Details
12.1.2 Company Description and Business Overview
12.1.3 Hormone Refractory Breast Cancer Introduction
12.1.4 AstraZeneca Revenue in Hormone Refractory Breast Cancer Business (2014-2019))
12.1.5 AstraZeneca Recent Development
12.2 AmpliMed Corporation
12.2.1 AmpliMed Corporation Company Details
12.2.2 Company Description and Business Overview
12.2.3 Hormone Refractory Breast Cancer Introduction
12.2.4 AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business (2014-2019)
12.2.5 AmpliMed Corporation Recent Development
12.3 Roche
12.3.1 Roche Company Details
12.3.2 Company Description and Business Overview
12.3.3 Hormone Refractory Breast Cancer Introduction
12.3.4 Roche Revenue in Hormone Refractory Breast Cancer Business (2014-2019)
12.3.5 Roche Recent Development
12.4 Bluefish Pharmaceuticals AB
12.4.1 Bluefish Pharmaceuticals AB Company Details
12.4.2 Company Description and Business Overview
12.4.3 Hormone Refractory Breast Cancer Introduction
12.4.4 Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business (2014-2019)
12.4.5 Bluefish Pharmaceuticals AB Recent Development
12.5 NeoCorp
12.5.1 NeoCorp Company Details
12.5.2 Company Description and Business Overview
12.5.3 Hormone Refractory Breast Cancer Introduction
12.5.4 NeoCorp Revenue in Hormone Refractory Breast Cancer Business (2014-2019)
12.5.5 NeoCorp Recent Development
12.6 Sanofi Genzyme
12.6.1 Sanofi Genzyme Company Details
12.6.2 Company Description and Business Overview
12.6.3 Hormone Refractory Breast Cancer Introduction
12.6.4 Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business (2014-2019)
12.6.5 Sanofi Genzyme Recent Development
12.7 Neopharm
12.7.1 Neopharm Company Details
12.7.2 Company Description and Business Overview
12.7.3 Hormone Refractory Breast Cancer Introduction
12.7.4 Neopharm Revenue in Hormone Refractory Breast Cancer Business (2014-2019)
12.7.5 Neopharm Recent Development
12.8 Boehringer Ingelheim GmbH
12.8.1 Boehringer Ingelheim GmbH Company Details
12.8.2 Company Description and Business Overview
12.8.3 Hormone Refractory Breast Cancer Introduction
12.8.4 Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business (2014-2019)
12.8.5 Boehringer Ingelheim GmbH Recent Development

13 Market Forecast 2019-2025
13.1 Market Size Forecast by Product (2019-2025)
13.2 Market Size Forecast by Application (2019-2025)
13.3 Market Size Forecast by Regions
13.4 North America
13.5 Europe
13.6 China
13.7 Japan
13.8 Southeast Asia
13.9 India
13.10 Central & South America

14 Analyst’s Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details

List of Tables and Figures

Table Hormone Refractory Breast Cancer Key Market Segments
Table Key Players Hormone Refractory Breast Cancer Covered
Table Global Hormone Refractory Breast Cancer Market Size Growth Rate by Type 2018-2025 (Million US$)
Figuer Tumor Markers Therapy Figures
Table Key Players of Tumor Markers Therapy
Figuer Gene Expression Therapy Figures
Table Key Players of Gene Expression Therapy
Figuer Gene Mutation Therapy Figures
Table Key Players of Gene Mutation Therapy
Table Global Hormone Refractory Breast Cancer Market Size Growth by Application 2019-2025 (Million US$)
Figure Global Hormone Refractory Breast Cancer Market Share by Application in 2018 & 2025
Figure Scientific Research and Production Case Studies
Figure Biological Science and Technology Case Studies
Figure Medical Technology Case Studies
Figure Medical Apparatus and Instruments Case Studies
Figure Hormone Refractory Breast Cancer Report Years Considered
Figure Global Hormone Refractory Breast Cancer Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Hormone Refractory Breast Cancer Market Size by Regions 2019-2025 (Million US$)
Table Global Hormone Refractory Breast Cancer Market Size by Regions 2019-2025 (Million US$)
Table Global Hormone Refractory Breast Cancer Market Share by Regions 2014-2019
Figure Global Hormone Refractory Breast Cancer Market Share by Regions 2014-2019
Figure Global Hormone Refractory Breast Cancer Market Share by Regions in 2018
Table Market Top Trends
Table Key Drivers: Impact Analysis (2019-2025)
Table Key Challenges
Figure PORTER'S FIVE FORCES ANALYSIS
Table Global Hormone Refractory Breast Cancer Revenue by by Players (2014-2019) (Million US$)
Table Global Hormone Refractory Breast Cancer Market Share by by Players (2014-2019)
Figure Global Hormone Refractory Breast Cancer Market Share by by Players in 2018
Table Global Hormone Refractory Breast Cancer by Players Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Hormone Refractory Breast Cancer Product/Solution/Service
Table Date of Enter into Hormone Refractory Breast Cancer Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Hormone Refractory Breast Cancer Market Size by Type (2014-2019) (Million US$)
Table Global Hormone Refractory Breast Cancer Market Size Share by Type (2014-2019)
Figure Global Hormone Refractory Breast Cancer Market Size Market Share by Type (2014-2019)
Table Global Hormone Refractory Breast Cancer Market Size by Application (2014-2019) (Million US$)
Table Global Hormone Refractory Breast Cancer Market Size Share by Application (2014-2019)
Figure Global Hormone Refractory Breast Cancer Market Size Market Share by Application (2014-2019)
Figure Global Hormone Refractory Breast Cancer Revenue Market Share by Application in 2018
Figure North America Hormone Refractory Breast Cancer Market Size 2014-2019 (Million US$)
Table North America Key Players Hormone Refractory Breast Cancer Revenue (2018-2019) (Million US$)
Table North America Key Players Hormone Refractory Breast Cancer Market Share (2018-2019)
Table North America Hormone Refractory Breast Cancer Market Size by Type 2014-2019 (Million US$)
Table North America Hormone Refractory Breast Cancer Market Share by Type 2014-2019
Table North America Hormone Refractory Breast Cancer Market Size by Application 2014-2019 (Million US$)
Table North America Hormone Refractory Breast Cancer Market Share by Application 2014-2019
Figure Europe Hormone Refractory Breast Cancer Market Size 2014-2019 (Million US$)
Table Europe Key Players Hormone Refractory Breast Cancer Revenue (2018-2019) (Million US$)
Table Europe Key Players Hormone Refractory Breast Cancer Market Share (2018-2019)
Table Europe Hormone Refractory Breast Cancer Market Size by Type 2014-2019 (Million US$)
Table Europe Hormone Refractory Breast Cancer Market Share by Type 2014-2019
Table Europe Hormone Refractory Breast Cancer Market Size by Application 2014-2019 (Million US$)
Table Europe Hormone Refractory Breast Cancer Market Share by Application 2014-2019
Figure China Hormone Refractory Breast Cancer Market Size 2014-2019 (Million US$)
Table China Key Players Hormone Refractory Breast Cancer Revenue (2018-2019) (Million US$)
Table China Key Players Hormone Refractory Breast Cancer Market Share (2018-2019)
Table China Hormone Refractory Breast Cancer Market Size by Type 2014-2019 (Million US$)
Table China Hormone Refractory Breast Cancer Market Share by Type 2014-2019
Table China Hormone Refractory Breast Cancer Market Size by Application 2014-2019 (Million US$)
Table China Hormone Refractory Breast Cancer Market Share by Application 2014-2019
Figure Japan Hormone Refractory Breast Cancer Market Size 2014-2019 (Million US$)
Table Japan Key Players Hormone Refractory Breast Cancer Revenue (2018-2019) (Million US$)
Table Japan Key Players Hormone Refractory Breast Cancer Market Share (2018-2019)
Table Japan Hormone Refractory Breast Cancer Market Size by Type 2014-2019 (Million US$)
Table Japan Hormone Refractory Breast Cancer Market Share by Type 2014-2019
Table Japan Hormone Refractory Breast Cancer Market Size by Application 2014-2019 (Million US$)
Table Japan Hormone Refractory Breast Cancer Market Share by Application 2014-2019
Figure Southeast Asia Hormone Refractory Breast Cancer Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Hormone Refractory Breast Cancer Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Hormone Refractory Breast Cancer Market Share (2018-2019)
Table Southeast Asia Hormone Refractory Breast Cancer Market Size by Type 2014-2019 (Million US$)
Table Southeast Asia Hormone Refractory Breast Cancer Market Share by Type 2014-2019
Table Southeast Asia Hormone Refractory Breast Cancer Market Size by Application 2014-2019 (Million US$)
Table Southeast Asia Hormone Refractory Breast Cancer Market Share by Application 2014-2019
Figure India Hormone Refractory Breast Cancer Market Size 2014-2019 (Million US$)
Table India Key Players Hormone Refractory Breast Cancer Revenue (2018-2019) (Million US$)
Table India Key Players Hormone Refractory Breast Cancer Market Share (2018-2019)
Table India Hormone Refractory Breast Cancer Market Size by Type 2014-2019 (Million US$)
Table India Hormone Refractory Breast Cancer Market Share by Type 2014-2019
Table India Hormone Refractory Breast Cancer Market Size by Application 2014-2019 (Million US$)
Table India Hormone Refractory Breast Cancer Market Share by Application 2014-2019
Figure Central & South America Hormone Refractory Breast Cancer Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Hormone Refractory Breast Cancer Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Hormone Refractory Breast Cancer Market Share (2018-2019)
Table Central & South America Hormone Refractory Breast Cancer Market Size by Type 2014-2019 (Million US$)
Table Central & South America Hormone Refractory Breast Cancer Market Share by Type 2014-2019
Table Central & South America Hormone Refractory Breast Cancer Market Size by Application 2014-2019 (Million US$)
Table Central & South America Hormone Refractory Breast Cancer Market Share by Application 2014-2019
Table AstraZeneca Company Details
Table AstraZeneca Revenue in Hormone Refractory Breast Cancer Business 2014-2019 (Million US$)
Figure AstraZeneca Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2014-2019)
Table AstraZeneca Recent Development
Table AmpliMed Corporation Company Details
Table AmpliMed Corporation Revenue in Hormone Refractory Breast Cancer Business 2014-2019 (Million US$)
Figure AmpliMed Corporation Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2014-2019)
Table AmpliMed Corporation Recent Development
Table Roche Company Details
Table Roche Revenue in Hormone Refractory Breast Cancer Business 2014-2019 (Million US$)
Figure Roche Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2014-2019)
Table Roche Recent Development
Table Bluefish Pharmaceuticals AB Company Details
Table Bluefish Pharmaceuticals AB Revenue in Hormone Refractory Breast Cancer Business 2014-2019 (Million US$)
Figure Bluefish Pharmaceuticals AB Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2014-2019)
Table Bluefish Pharmaceuticals AB Recent Development
Table NeoCorp Company Details
Table NeoCorp Revenue in Hormone Refractory Breast Cancer Business 2014-2019 (Million US$)
Figure NeoCorp Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2014-2019)
Table NeoCorp Recent Development
Table Sanofi Genzyme Company Details
Table Sanofi Genzyme Revenue in Hormone Refractory Breast Cancer Business 2014-2019 (Million US$)
Figure Sanofi Genzyme Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2014-2019)
Table Sanofi Genzyme Recent Development
Table Neopharm Company Details
Table Neopharm Revenue in Hormone Refractory Breast Cancer Business 2014-2019 (Million US$)
Figure Neopharm Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2014-2019)
Table Neopharm Recent Development
Table Boehringer Ingelheim GmbH Company Details
Table Boehringer Ingelheim GmbH Revenue in Hormone Refractory Breast Cancer Business 2014-2019 (Million US$)
Figure Boehringer Ingelheim GmbH Revenue Growth Rate in Hormone Refractory Breast Cancer Business (2014-2019)
Table Boehringer Ingelheim GmbH Recent Development
Table Global Hormone Refractory Breast Cancer Market Size by Regions (Million US$) 2019-2025
Figure Global Hormone Refractory Breast Cancer Market Size Share by Regions (2019-2025)
Figure Global Hormone Refractory Breast Cancer Market Size Share by Regions in 2025
Figure North America Hormone Refractory Breast Cancer Market Size Forecast (2019-2025)(Million USD)
Figure Europe Hormone Refractory Breast Cancer Market Size Forecast (2019-2025)(Million USD)
Figure China Hormone Refractory Breast Cancer Market Size Forecast (2019-2025)(Million USD)
Figure Japan Hormone Refractory Breast Cancer Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Hormone Refractory Breast Cancer Market Size Forecast (2019-2025)(Million USD)
Figure India Hormone Refractory Breast Cancer Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Hormone Refractory Breast Cancer Market Size Forecast (2019-2025)(Million USD)
Table Global Hormone Refractory Breast Cancer Market Size by Product (2019-2025) (Million US$)
Figure Global Hormone Refractory Breast Cancer Market Size by Product (2019-2025)
Figure Global Hormone Refractory Breast Cancer Market Size by Product in 2025
Table Global Hormone Refractory Breast Cancer Market Size by Application (2019-2025) (Million US$)
Figure Global Hormone Refractory Breast Cancer Market Size by Application (2019-2025)
Figure Global Hormone Refractory Breast Cancer Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources

【掲載企業】

AstraZeneca、AmpliMed Corporation、Roche、Bluefish Pharmaceuticals AB、NeoCorp、Sanofi Genzyme、Neopharm、Boehringer Ingelheim GmbH

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ ホルモン抵抗性乳癌の世界市場：規模・現状・予測(Global Hormone Refractory Breast Cancer Market Size, Status and Forecast 2019-2025)]についてメールでお問い合わせはこちらでお願いします。

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 GlobalResearch.jp